# To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2

> **NCT05895110** · NA · COMPLETED · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 240 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant Novel Coronavirus vaccine (CHO Cells)

## Key facts

- **NCT ID:** NCT05895110
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-29
- **Primary completion:** 2022-11-19
- **Final completion:** 2022-11-19
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05895110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05895110, "To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05895110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*